| Autor: |
Vance RB, Knight WA 3rd, Chen TT, Costanzi JJ, LoBuglio AF |
| Jazyk: |
angličtina |
| Zdroj: |
Investigational new drugs [Invest New Drugs] 1983; Vol. 1 (1), pp. 89-93. |
| DOI: |
10.1007/BF00180196 |
| Abstrakt: |
One hundred and eight patients with non-small cell lung cancer were treated in a Phase II trial with MGBG at a dose of 600 mg/m2 i.v. weekly. Partial responses were noted in 3/43 patients with adenocarcinoma and 1/40 with squamous cell carcinoma. No responses were noted in 24 patients with large cell carcinoma. Overall, the drug was reasonably well-tolerated. At this dosage and schedule, MGBG has no substantial antitumor activity for patients with non-small cell lung cancer. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
